Shots:

• The P-III (EDELWEISS 3) trial evaluates linzagolix (200/75mg, qd) with/out ABT vs PBO in 484 women with EAP. The results from the post-treatment follow-up & extension study are expected in Q2’22 & Q4’22
• Linzagolix (200mg) met co-primary efficacy objectives i.e., reductions in DYS & NMPP @3mos., improvements in 2EPs of DYS, NMPP, dyschezia, overall pelvic pain & ability to perform daily
• Additionally, linzagolix (75mg) without ABT showed an improvement in DYS & 2EPs @6mos. but failed to meet co-primary objective of reduction in NMPP @3mos., responder rates for DYS & NMPP (73% & 47% for 200mg & 44% & 39% for 75mg vs 24% & 31%), were well-tolerated with BMD decrease

Ref: Globe Newswire | Image: Businesswire